International Registry Launched to Study Long-Term Effects of AngioDynamics NanoKnife for Prostate Cancer

October 23, 2024—AngioDynamics, Inc. announced the launch of an international multicenter prospective registry study that will assess the long-term effects of treating men with unifocal intermediate-risk prostate cancer using the company’s NanoKnife system.

AngioDynamics is conducting the investigator-initiated study in partnership with the University College London Hospital (UCLH) in London, United Kingdom.

According to the company, the NanoKnife system is an alternative to conventional radical surgery or radiotherapy. Using a nonthermal approach, the NanoKnife system is engineered to preserve vital structures inside and outside the prostate with the aim of providing effective treatment of tumors, low complication rates, and minimal impact on quality of life.

The United Kingdom’s National Institute for Health and Care Excellence upgraded the use of the NanoKnife system from “Research Only” to “Special Arrangements” in 2023, allowing hospitals to start new services while collecting more data and signaling its acceptance in national urology guidelines, advised AngioDynamics.

As summarized in the press release, the study will enroll a minimum of 500 patients worldwide to confirm the findings of multiple published papers from single-center studies indicating that the NanoKnife system is safe and effective in the treatment of targeted tumors and prevents or delays the need for radical intervention while preserving patient quality of life.

The company further advised that the study will complement ongoing randomized controlled trials evaluating NanoKnife versus radical treatment.

The study will closely monitor patients posttreatment, measuring critical quality of life metrics and tracking any necessary follow-up interventions. In addition to quality of life, the study will assess overall and prostate-specific mortality rates, noted the press release.

According to AngioDynamics, UCLH was the first facility in the National Health Service to use the NanoKnife system to treat prostate cancer and provide standardized patient selection, treatment, and long-term follow-up. Also, UCLH is the largest center for robotic prostate surgery in the United Kingdom and is a leading provider of focal therapy, radiotherapy, robotic surgery, and active surveillance treatment options for men with prostate cancer, noted the company.

Professor Mark Emberton, MD, Interventional Oncology, Division of Surgery and Interventional Science at UCHL, commented on the study in AngioDynamics’ press release.

“The international registry will allow us to track patients’ outcomes over time and allow us to quality control the dissemination of this novel technology across the world,” stated Prof. Emberton. “This will enable us to learn from every patient treated and, as a result, continue to refine this treatment that allows men to have their prostate cancer treated and maintain their quality of life.”